| Principles of adoptive T cell therapy in cancer Ö Met, KM Jensen, CA Chamberlain, M Donia, IM Svane Seminars in immunopathology 41, 49-58, 2019 | 216 | 2019 |
| INDEL detection, the ‘Achilles heel’of precise genome editing: a survey of methods for accurate profiling of gene editing induced indels EP Bennett, BL Petersen, IE Johansen, Y Niu, Z Yang, CA Chamberlain, ... Nucleic acids research 48 (21), 11958-11981, 2020 | 72 | 2020 |
| T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression R Andersen, TH Borch, A Draghi, A Gokuldass, MAH Rana, M Pedersen, ... Annals of Oncology 29 (7), 1575-1581, 2018 | 69 | 2018 |
| Differential effects of corticosteroids and anti‐TNF on tumor‐specific immune responses: implications for the management of irAEs A Draghi, TH Borch, HD Radic, CA Chamberlain, A Gokuldass, IM Svane, ... International Journal of Cancer 145 (5), 1408-1413, 2019 | 48 | 2019 |
| Acquired resistance to cancer immunotherapy A Draghi, CA Chamberlain, A Furness, M Donia Seminars in immunopathology 41, 31-40, 2019 | 43 | 2019 |
| Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types AH Kverneland, CA Chamberlain, TH Borch, M Nielsen, SK Mørk, ... Journal for immunotherapy of cancer 9 (10), 2021 | 37 | 2021 |
| Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy CA Chamberlain, EP Bennett, AH Kverneland, IM Svane, M Donia, Ö Met Molecular Therapy-Oncolytics 24, 417-428, 2022 | 32 | 2022 |
| Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma … A Gokuldass, A Draghi, K Papp, TH Borch, M Nielsen, MCW Westergaard, ... Cancers 12 (11), 3344, 2020 | 23 | 2020 |
| ACT up TIL now: the evolution of tumor-infiltrating lymphocytes in adoptive cell therapy for the treatment of solid tumors TM Hulen, CA Chamberlain, IM Svane, Ö Met Immuno 1 (3), 194-211, 2021 | 20 | 2021 |
| Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor … A Draghi, CA Chamberlain, S Khan, K Papp, M Lauss, S Soraggi, ... Frontiers in Immunology 12, 705422, 2021 | 18 | 2021 |
| Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R) IM Chen, M Donia, CA Chamberlain, AWP Jensen, A Draghi, S Theile, ... European Journal of Cancer 180, 125-133, 2023 | 14 | 2023 |
| β-Lactamase tools for establishing cell internalization and cytosolic delivery of cell penetrating peptides SR Stone, T Heinrich, SM Juraja, JN Satiaputra, CM Hall, M Anastasas, ... Biomolecules 8 (3), 51, 2018 | 13 | 2018 |
| The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro M Presti, MCW Westergaard, A Draghi, CA Chamberlain, A Gokuldass, ... Cancer Immunology, Immunotherapy 70, 1771-1776, 2021 | 10 | 2021 |
| Coexisting alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post–PD-1 immunotherapy M Nielsen, M Presti, Z Sztupinszki, AWP Jensen, A Draghi, ... Cancer immunology research 10 (10), 1254-1262, 2022 | 9 | 2022 |
| Transcriptomic signatures of tumors undergoing T cell attack A Gokuldass, A Schina, M Lauss, K Harbst, CA Chamberlain, A Draghi, ... Cancer Immunology, Immunotherapy, 1-11, 2022 | 7 | 2022 |
| Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma A Draghi, M Presti, AWP Jensen, CA Chamberlain, B Albieri, ... Clinical Cancer Research 29 (19), 3937-3947, 2023 | 5 | 2023 |
| 1022MO Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients AH Kverneland, TH Borch, C Chamberlain, CL Lorentzen, M Nielsen, ... Annals of Oncology 31, S706, 2020 | 4 | 2020 |
| Combined detection of CD137 and type 1 functions improves identification and characterization of the activated T lymphocyte repertoire A Draghi, A Gokuldass, CA Chamberlain, HD Radic, IM Svane, M Donia Annals of Oncology 30, xi58, 2019 | 1 | 2019 |
| Analyzing functional heterogeneity of effector cells for enhanced adoptive cell therapy applications TM Hulen, DL Petersen, MJ Jacobsen, MJ Mikkelsen, Ö Met, M Donia, ... | | 2024 |
| Biomarkers of response and acquired resistance to TIL-ACT in solid tumors W Robinson, A Castro, M Al-Bakir, JJ Gartner, CA Chamberlain, ... Cancer Research 84 (6_Supplement), 1-1, 2024 | | 2024 |
